Abstract 2245
Background
Cancer care costs are a major concern for patients and society. We aimed to assess real life costs for the medical management of uMM.
Methods
We performed a retrospective patient chart review collecting data on demographics, disease characteristics and management. A complete registry of patients diagnosed with melanoma at the Antwerp University Hospital between 2007 and 12/2017 was compiled. Eligible for this chart review were all patients with uMM with sufficient data available and who either had an observation period of > 1 year at the time of this review or who deceased before December 31, 2017. Direct costs were calculated by multiplying each item of resource use, obtained from each individual patient chart, with its unit cost (2018, €) using the Belgian public health care payer’s perspective (PHCP) and patient’s perspective. A Kaplan–Meier sample average (KMSA) estimator was used to weight expected costs by the probability of survival and to adjust for censored data.
Results
89 patients fulfilled all eligibility criteria for this chart review. Ten of the patients (11%) are still alive. 9 patients (10%) received best supportive care (BSC) only. 40 patients (45%) received > 1 immunotherapy or targeted agent. Mean overall monthly cost/patient for the entire cohort was € 7,244, of which € 7,153 was covered by the public health care payer. The cost was driven by systemic treatment costs (69% of cost). Median overall survival (OS) was 8.18 months (95 % CI: 6.0-10.3). Mean monthly overall cost was € 9,269 for patients (n = 40) with potential access to anti-PD1, anti-CTLA-4, BRAFi, and MEKi; median OS in this cohort was 13.83 months (95 % CI: 8.6-19.0). Mean monthly overall cost was € 3,258 for patients (n = 33) treated with chemotherapy/BSC only. Median OS in this cohort was 3.91 months (95 % CI: 2.2-5.6). Mean monthly overall cost was € 5,398 for patients (n = 16) who had access to anti-CTLA-4 and/or BRAFi but not to MEKi and anti-PD1. Median OS in these patients was 11.0 months (95 % CI 7.5-14.6).
Conclusions
Management of uMM results in considerable costs for the PHCP, mainly driven by systemic treatment costs. Also in a real-life setting, the introduction of immunotherapy and targeted agents substantially improved survival. However, mean monthly cost has nearly tripled.
Clinical trial identification
Legal entity responsible for the study
Antwerp University Hospital.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1159 - Molecular characterization and search for founding effects in Canarian families with Hereditary Breast and Ovarian Cancer Syndrome
Presenter: Elisenda Llabres Valenti
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3725 - Effect of the polymorphism rs2066844 of the NOD2 gene on colon cancer incidence in a high cardiovascular risk population. Modulation by gender
Presenter: Judith Begona Ramirez Sabio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3708 - Effect of the polymorphisms rs1476413, rs1801131, rs4846052 and rs6541003 of the MTHFR gene on prostate cancer in a high cardiovascular risk population
Presenter: Judith Begona Ramirez Sabio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5057 - Association of a genetic variant in cyclin-dependent kinase Inhibitor 2A gene with the increased risk of breast cancer
Presenter: Soodabeh Shahid Sales
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5970 - Investigating the role of HAT protein TIP60 in regulating functional dynamics of nuclear receptor PXR
Presenter: KARISHMA BAKSHI
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1360 - The role of downregulated SIRT3 expression in patients with hepatocellular carcinoma
Presenter: Hanhee Jo
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1634 - Prediction and Intervention of Colorectal Cancer Risk with Artificial Intelligent System
Presenter: Yang Ge
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4921 - Measuring the Efficiency of Cancer Care in Europe
Presenter: Rikard Althin
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1235 - Circulating cell-free DNA isolated from plasma of mesenteric veins predicts prognosis in stage II colorectal cancer patients
Presenter: Chih-Yung Yang
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5169 - _lonality of uterine carcinosarcoma as a factor of clinical prognosis.
Presenter: Natalia Levitskaya
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract